XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
P/B ratio for XBiotech Inc. (XBIT)
P/B ratio as of 2023: 0.55
According to XBiotech Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.55. At the end of 2022 the company had a P/B ratio of 0.44.
P/B ratio history for XBiotech Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.55 |
| 2022 | 0.44 |
| 2021 | 1.24 |
| 2020 | 1.38 |
| 2019 | 0.96 |
| 2018 | 4.39 |
| 2017 | 2.28 |
| 2016 | 5.55 |
| 2015 | 3.25 |
| 2014 | 12.49 |
| 2013 | 72.10 |
| 2012 | 100.03 |